Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus
AssigneeThe Board of Trustees of the University of Illinois
InventorsEric Oldfield, Yongcheng Song
Life of this patent
Estimating the term…
Abstract
This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus.
Claims27
A compound of the formula
- wherein:
- Y is selected from the group consisting of:
- —P(O)(O−M1)(O−M2), —P(O)(OH)2, —P(O)(OH)(O−M3), —SO3H, —SO3−M4, —C(O)O−M5 and —COOH;
- X is selected from the group consisting of:
- —C(O)—, —S(O2)—, —P(O)(O−M6)-, and —CH2—;
- T is selected from the group consisting of:
- —O—, —CH2—, and —NR3—;
- A is a bridging diradical selected from the group consisting of:
- —(CH2)n—, —(C6H4)n—, —(CF2)n—, —(CCl2)n—, —(CBr2)n—, alkylene, substituted alkylene, arylene, substituted arylene, alkylenearylene, substituted alkylenearylene, arylenealkylene, substituted arylenealkylene, alkylenearylenealkylene, substituted alkylenearylenealkylene, oxyalkylene, substituted oxyalkylene, oxyalkylenearylene, substituted oxyalkylenearylene, oxyarylene, substituted oxyarylene, oxyarylenealkylene, and substituted oxyarylenealkylene;
- n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
- M1, M2, M3, M4, M5, M6, M7 are each independently a pharmaceutically acceptable cation;
- R3 is selected from the group consisting of:
- —H, —OH, —O−M7, aryl, substituted aryl, alkyl, substituted alkyl, —COOH, —COO−, —CO—NH2, —(CH2)n—O—CO—, and halo;
- R4 and R5 are each independently selected from the group consisting of —H, —OH, —O−M7, aryl, substituted aryl, alkyl, substituted alkyl, —COOH, —COO−, —CO—NH2, —(CH2)n—COOH, —(CH2)n—COO−, and halo;
- R1, R2, R6, R7, R8 are each independently selected from the group consisting of:
- aryl, substituted aryl, alkyl, substituted alkyl, —COOH, —COO−, —CO—NH2, —(CH2)n—O—CO—, halo, and the following substituents:
(canceled)
13-14. (canceled)
A method of selectively inhibiting microbial activity comprising contacting a microbe with a compound wherein the compound is capable of inhibiting a CrtM activity or STX biosynthesis and has a limited capability for inhibiting or substantially inhibiting human cholesterol biosynthesis or human squalene synthase (hSQS).
17-19. (canceled)
(canceled)
(canceled)
27-31. (canceled)
34-38. (canceled)
Dependencies are inferred from the claim text.